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Abstract 
 
Introduction: Cardiovascular disease (CVD) is among the leading causes of death 
worldwide, and is strongly influenced by lifestyle. Thus, promoting a healthy lifestyle, which 
includes having a healthy diet, is among the primary preventive strategies for reducing future 
risk of cardiovascular events. Elevated circulating total homocysteine (tHcy) is an 
independent risk factor for CVD. However, Hcy lowering treatment has not proven to reduce 
mortality or cardiovascular events among patients with CVD, and the mechanism linking 
tHcy to disease risk has not yet been discovered. Thus, the metabolic pathways surrounding 
Hcy, including the one-carbon metabolism and the choline oxidation pathway, are very 
interesting targets for investigation. 
 Betaine is a micronutrient that is achieved mainly from the diet or endogenously by 
irreversible mitochondrial oxidation of choline. Betaine lowers tHcy concentrations in the 
liver and kidney by serving as a methyl donor in a reaction catalyzed by betaine-
homocysteine methyltransferase. This reaction represents the first step along a 
transmethylation pathway, which provides three available methyl groups in the one-carbon 
metabolism. Betaine is thus considered to be an important modulator of the one-carbon 
metabolism. Furthermore, betaine-dependent remethylation of Hcy produces methionine. 
Betaine has thus been hypothesized to affect the hepatic lipid metabolism by producing 
sufficient amounts of methionine which enters a pathway that ultimately leads to increased 
synthesis and secretion of lipid-rich very-low density lipoproteins (VLDLs). 
 
Objective: The main aim of the current study was to explore the associations of reported 
dietary betaine intake with circulating levels of metabolites along to the choline oxidation 
pathway and lipid related parameters in patients diagnosed with stable angina pectoris (SAP). 
A secondary aim was to explore potential effect modification by folate status and statin 
treatment. 
 
Methods: This cross-sectional study was based on the Western Norway B-vitamin 
Intervention Trial, and included 2026 SAP patients with angiographically verified coronary 
artery disease, and available dietary data. Average daily dietary intakes during the recent year 
were assessed by a 169-item food frequency questionnaire. Standard blood laboratory 
parameters were measured according to routine protocols at the two university hospitals in 
Western Norway. The associations between reported dietary betaine intake and one-carbon 
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metabolites, including choline oxidation, were assessed by Spearman´s rank correlations, 
adjusted for age, gender, total energy intake and statin treatment. Multiple linear regression 
was used to explore the relationship between reported dietary betaine intake by quartiles and 
according to the upper decile, and levels of lipid related parameters, and were adjusted for 
age, gender, body mass index (BMI), total energy intake, current smoking, statin treatment 
and diabetes. We also evaluated the effect modification by folate status and statin treatment in 
these linear regression analyses. 
 
Results: Median dietary betaine intake in this cohort was 134 mg/d. The participants (80.4% 
males) had a median age of 62 years. Unadjusted Spearman correlation analyses revealed a 
positive association of dietary betaine intake with plasma betaine (r=0.17, p<0.001), DMG 
(r=0.06; p=0.006) and sarcosine (r=0.12, p<0.001) and an inverse association with tHcy  
(r=-0.09, p<0.001). The association with plasma betaine was attenuated by adjusting for age, 
gender, total energy intake and statin treatment, but none of the other associations were 
appreciably affected by such adjustment. Furthermore, in the unadjusted linear regression 
analyses increasing intakes were associated with lower levels of serum LDL-, HDL-, and total 
cholesterol, Apo B and Apo A1. Adjusted multiple linear regression analysis demonstrated no 
significant associations between quartiles of betaine intake and lipid related parameters and 
no effect modification with folate status or statin treatment was observed. However a 
particular high intake corresponding to the upper decile was associated with significantly 
higher plasma HDL-cholesterol and lower Apo B levels. Subgroup analyses revealed this 
association to be restricted to those with a serum folate level above median. Furthermore, 
participants with particular high betaine intake and who were treated with statins had 
significantly lower plasma LDL-cholesterol and Apo B levels, while no such associations 
were seen in those not using statins. 
 
Conclusion: In the present study among 2026 patients with SAP, there was a significant 
positive association between reported dietary betaine intake and circulating betaine, DMG and 
sarcosine, and a significant inverse association with circulating tHcy. A particular high 
betaine intake corresponding to the upper decile was associated with significantly higher 
HDL-cholesterol and lower Apo B. A beneficial effect of high betaine on the lipid profile 
tended to be restricted to patients with high serum folate and to those treated with statins. 
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1.0 Introduction 
 
1.1 Cardiovascular disease 
 
Cardiovascular disease (CVD) is a collective term for several pathological conditions in the 
heart, vascular system or pericardium [1]. CVD remains a leading cause of death in Western 
countries, causing nearly one-third of all deaths worldwide [2]. The majority of CVDs are 
pathologies in the arterial circulation, collectively referred to as atherothrombotic CVD, due 
to their clinical manifestations, often in the form of thromboembolic complications [3]. 
Atherothrombotic CVD (hereafter referred to as CVD) is usually caused by arteriosclerosis, 
and includes coronary heart disease (CHD), cerebrovascular disease, diseases of the aorta and 
peripheral arterial disease [1]. Among the CVDs, CHD is the major cause of CVD related 
deaths [2]. 
 
1.2 Coronary heart disease 
 
CHD occurs when the coronary vessels have a decreased capacity to deliver oxygen-rich 
blood to the heart [1, 4]. The metabolic changes that occur in tissues due to reduced oxygen 
delivery are called ischemia, and CHD is therefore often called ischemic heart disease [4]. 
Ischemia in the heart may typically cause chest pain, known as angina pectoris [5, 6]. Patients 
are further diagnosed with stable angina pectoris (SAP) if the chest pain symptoms remain 
stable for usually 60 days, in contrast to unstable angina pectoris [6]. In the majority, 
however, CHD usually first manifest itself as an acute coronary syndrome (ACS), including 
unstable angina, acute myocardial infarction (MI), severe arrhythmia or sudden cardiac death 
[1, 4]. Thus, a large proportion of patients with prevalent SAP includes patients previously 
suffered and treated from ACS [6]. The prevalence of SAP was estimated to be 17.2 million 
in Europe and 54.0 million worldwide in 2004 [7].  
 
1.3 Arteriosclerosis 
 
The disease processes of the arterial wall, which includes chronic inflammation and hardening 
of the arteries is called arteriosclerosis [8]. A main underlying pathophysiologic mechanism 
of arteriosclerosis development is often so-called atherosclerosis [9], characterized by the 
presence of an atheroma within the arterial lining. The atheroma includes inflammatory cells 
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like monocytes and macrophages, which have been turned into so-called foam cells due to a 
large uptake of cholesterol and other lipids [8, 10]. Recently, such foam cells have been 
shown also to be of smooth muscle cell origin. Excess foam cell formation or other stimuli of 
apoptosis may cause the foam cells to rupture, and free cholesterol and cholesterol crystals 
stimulate the inflammatory process, which may promote so-called plaque rupture, a typical 
underlying feature of an ACS [4]. Thus, lipid metabolism is crucially involved in 
arteriosclerosis related clinical events. Elevated plasma cholesterol levels, the oxidation of 
low-density lipoprotein (LDL) particles and their retention in the arterial intima are 
considered primary elements of this process [11]. The development is usually slow, but has a 
high potential of rapid progress.  
 
1.4 Risk factors for CVD 
 
Based primarily on data from a number of large-scale epidemiological observational studies 
during the last 50 years, factors related to a so-called unhealthy lifestyle like smoking, 
physical inactivity, unhealthy dietary habits, obesity, diabetes, hypertension and 
hyperlipidemia are associated with increased risk of CVD [12-19]. In addition, non-
modifiable risk factors for CVD are age, gender, and family history, where future risk 
increases if a first-degree relative have suffered from CVD before the age of 55 years for 
males and 65 years for females [2]. Due to the strong influence of lifestyle, CVD is included 
among the typical lifestyle diseases [20]. Thus, promoting a healthy lifestyle, which includes 
having a healthy diet, is essential in the prevention of this disease, also among those receiving 
medical treatment for this condition, as recommended by the American Heart Association and 
the European Society of Cardiology [21, 22]. 
 
1.5 Diet and CVD 
 
The association between dietary intake of both saturated fat and trans fat and risk of CHD has 
been well established [23, 24]. Thus, as part of a healthy diet the American Heart Association 
recommends dietary intake of saturated fat and trans fat restricted to <7% and <1% of the 
total daily energy intake (EI), respectively [21]. The same guideline advocates the 
replacement of saturated fat with mono- and polyunsaturated fat [21, 22], which has 
previously been shown to significantly reduce risk of CHD [25-27]. However, recent findings 
from meta-analyses of observational studies and randomized controlled-trials now questions 
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the established association between intake of saturated fat intake and risk of CHD [23, 28-30]. 
Moreover, compared to dietary fat, epidemiologic studies on the association between dietary 
protein intake and risk of CHD are limited, whereas data on overall protein intake from 
observational and prospective cohort studies are not supportive for such an association [31-
33]. Intake of read meat may be associated with elevated risk [32, 34, 35], while intake of soy 
may be protective [36-38]. Furthermore, dietary intake of carbohydrates with a high glycemic 
index has been significantly associated with increased risk of CHD, when compared with 
carbohydrates with a low glycemic index, which do not increase disease risk [39-41].  
 
Dietary intake of various fruits and vegetables, in addition to various types of grains, 
cereals and dietary fiber is essential in a healthy daily diet, as recommended by the American 
Heart Association [21], and has been associated with a decreased risk of CVD [42-48]. A 
recent randomized trial reported that a Mediterranean diet supplemented with extra virgin oil 
and mixed nuts reduced cardiovascular events [49]. The Mediterranean diet typically includes 
a high intake of olive oil, fruit, nuts, vegetables, cereals, and fish, while poultry, dairy 
products and read meat are kept at a moderate level. According to a systemic review, this type 
of diet appeared to be the most protective diet against CHD [50]. Lastly, lower-than-normal 
plasma levels of antioxidants as a result of low vitamin intake has been associated with excess 
risk of CHD [51]. However, according to a recent meta-analysis of randomized controlled 
trials there is no evidence to support that supplementation with antioxidants or vitamins 
reduces the increased risk of CVD [52]. This includes B-vitamins, as demonstrated in the two 
Norwegian studies, the Norwegian Vitamin Intervention Trial and the Western Norway B-
vitamin Intervention Trial (WENBIT), whose main aim was to test whether lowering of 
plasma total homocysteine (tHcy) could slow the progression of CHD and reduce mortality in 
patients with established CHD [53, 54]. 
 
1.6 One-carbon metabolism 
 
An elevated plasma or serum tHcy level, known as hyperhomocysteinemia is regarded as an 
independent risk factors for CVD [2, 55-60], and has been associated with premature vascular 
disease [61-65], and with overall risk of mortality among patients with angiographically 
verified coronary artery disease (CAD) [56, 59]. Hyperhomocysteinemia was assumed to play 
a causative role in the development of atherosclerosis [55], and may be due to a defect in 
remethylation or transsulfuration pathways of Hcy metabolism or by increased production 
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[66, 67]. Because treatment with folic acid lowers tHcy levels and folic acid is a precursor for 
5-methyltetrahydrofolate (5-mTHF), which serves as a methyl donor in the remethylation of 
Hcy, it was hypothesized that treatment with folic acid would reduce CVD incidence and 
mortality through increased remethylation of Hcy by increasing methionine synthase activity 
[68]. However, it has later been demonstrated that increased serum folate concentrations 
reduce tHcy by being an inhibitor of methyltransferases like glycine N-methyltransferase 
(GNMT) [69], hereby reducing the Hcy production to spare S-adenosylmethionine (SAM) for 
other methylation reactions, including methylation of RNA, DNA and proteins, and the 
formation of phosphatidylcholine (PC) [70]. GNMT inhibition has recently been linked with 
impaired cholesterol export from the liver or peripheral tissues and with atherosclerosis 
development [71] which could explain the increased rapid progression of CAD observed after 
folic acid / B12 treatment in WENBIT [72]. Folate has thus been suggested to influence the 
activity of betaine homocysteine methyl transferase (BHMT) [73], which uses betaine as 
methyldonor for the alternative remethylation of Hcy. 
 
BHMT is a cytosolic zinc metalloenzyme, expressed at a high level in the liver and 
kidney, where it catalyzes the transfer of a methyl group from betaine to Hcy, which is 
converted to dimethylglycine (DMG) and methionine, respectively, as shown in Figure 1. 
Betaine is therefore essential in order to lower tHcy and maintain methionine concentrations 
[74]. Furthermore, because Hcy also is remethylated by 5-mTHF in most tissues [68], the 
metabolism of betaine and folate converges at the point where Hcy resides [75, 76]. 
Moreover, the betaine-dependent remethylation of Hcy in the BHMT reaction represents the 
first step along a transmethylation pathway, where three methyl groups are made available. 
After DMG have been synthesized from betaine, it enters the mitochondrion where it is 
demethylated to sarcosine, also known as monomethylglycine [77]. Sarcosine is subsequently 
demethylated to glycine, which is further interconverted to serine, degraded by the glycine 
cleavage system, or exported out of the mitochondria.   
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Figure 1: Schematic overview over the one-carbon and homocysteine metabolism. 
Abbreviations: Cho, Choline; Bet ald, Betaine aldehyde, Bet, Betaine; BHMT, Betaine-homocysteine 
methyltransferase; DMG, Dimethylglycine; Sarc, Sarcosine; Gly, Glycine; Ser, Serine; Met, 
Methionine; Hcy, Homocysteine; THF, Tetrahydrofolate; 5-mTHF, 5-mehtyltetrahydrofolate.  
 
 
1.7 Betaine 
 
1.7.1 Dietary sources 
 
Betaine (N, N, N-trimethylglycine) is a small methyl derivate of the amino acid glycine, 
containing three chemically reactive methyl groups [75]. It is often referred to as glycine 
betaine, from now on denoted as betaine, which originally was discovered in sugar beet (Beta 
vulgaris) [78]. Betaine is abundant in microorganisms, plants and animals and is found in a 
huge variety of dietary sources [79-82]. Important sources of betaine are plant-based foods, 
especially cereal foods, such as refined and whole grain wheat, as shown in Table 1 [82-84]. 
Because betaine is synthesized de novo by the irreversible mitochondrial oxidation of choline, 
it can also be obtained from choline-containing foods [67]. In 1998, the Food and Nutrition 
board of the Institute of Medicine recognized choline as an essential micronutrient, and 
recommended an Adequate Intake of 550 and 425 mg/d for men and women, respectively [85, 
86] Even though betaine is an important nutrient, it is not considered as an essential 
micronutrient, and as far as we know, no official recommendations of a daily intake has been 
Hcy
Met
BHMT
Bet
DMGTHF
5-mTHF
Cystathionine Bet ald
Cho
Sarc Gly
Cysteine
Ser
MitochondrionCytosol
Cho
Ser
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made [84]. However, dietary intakes have been estimated to range between 100 and 300 mg/d 
in Europe and the US [87-91].  
 
Table 1: Betaine content in selected foods1  
Food item Betaine content  (mg/100g) 
Wheat germ  410 
Cereals, all bran  360 
Wheat bran  320 
Beets, canned  260 
Spaghetti, dry  140 
Rye flour, dark  150 
Spinach, raw  130 
Wheat bread    85 
Fish, portions and sticks    45 
Sweet potato    35 
Sunflower seeds kernel, dried    35 
Shrimp, canned    23 
Nuts, cashew nuts    11 
Beef and pork products      0.2 – 17.0 
1 Collected from Patterson, K. et al. 2008, USDA database for the choline content of common foods.  Release two. 
 
 
1.7.2 Biochemistry 
 
Betaine is a zwitterionic quaternary ammonium compound at neutral pH, giving it the 
property of being a highly polar and lipophobic compound, which is easily soluble in water 
and almost insoluble in various organic solvents [67, 78]. Betaine can be achieved trough the 
diet from a wide range of animal and plant sources, or by de novo synthesis in tissues from 
choline [84]. Following ingestion, betaine is absorbed through the small intestine via the 
duodenum by active Na+ or Cl- coupled transport, and by passive Na+ independent transport 
systems, and is assumed to have a very high bioavailability close to 100% [67, 75]. Because 
betaine is an N-methylated amino acid, the active transport is carried out by amino acid 
transport systems, predominantly by betaine/ γ-aminobutyric acid transport and amino acid 
transport system A [92]. De novo synthesis mainly occurs in the liver and kidneys, from 
choline by mitochondrial oxidation in a two-step enzymatic reaction, as demonstrated in 
Figure 2 [93]. First, choline is oxidized to the intermediate substrate betaine aldehyde by the 
mitochondrial enzyme choline oxidase, also known as choline dehydrogenase (CHDH). The 
enzyme is a flavoprotein localized in the inner mitochondrial membrane, where it is a part of 
the respiratory chain [94]. For each molecule of choline oxidized, two molecules of adenosine 
triphosphate are generated [93]. In the second enzymatic reaction, betaine aldehyde is further 
oxidized to betaine by a second mitochondrial enzyme, betaine aldehyde dehydrogenase 
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(BADH), which uses vitamin B3 (nicotinamide adenine dinucleotide) as a cofactor. This two-
step enzymatic reaction of choline to betaine is irreversible [95]. 
 
 
 
Figure 2: Endogenous betaine synthesis. Abbreviations: CHDH, Choline dehydrogenase; Bet ald, 
Betaine aldehyde; BADH, Betaine aldehyde dehydrogenase; BHMT, Betaine-homocysteine 
methyltransferase; DMG, dimethylglycine. 
 
 
1.7.3 Biological function 
 
In mammals, betaine has two principal physiological roles, which include being an organic 
osmolyte and a methyl donor. As a methyl donor, betaine participates in the remethylation of 
Hcy, catalyzed by BHMT in the liver and kidney, which forms methionine and DMG from 
Hcy and betaine, respectively [73, 75]. In the liver, this pathway is considered to be 
responsible for about 50% of the Hcy methylation capacity, implying that betaine is of great 
importance concerning the formation of methionine and maintaining its concentrations in this 
organ [78]. Furthermore, the activity of BHMT is suggested to be osmoregulated [96]. Thus, 
the roles of betaine as an osmolyte and as a methyl donor depend upon each other. When 
intracellular concentrations of osmolytes need to be maintained, the expression of BHMT is 
downregulated [96, 97], thereby reducing the catabolism of betaine through the 
transmethylation pathway, making fewer methyl groups available in the one-carbon 
metabolism [78]. 
 
As an organic osmolyte, betaine accumulates in most tissues to regulate cell volume 
and modulate intracellular osmolarity, and thus protects cells against osmotic stress when 
Cytosol
Mitochondrion
Choline
Bet aldCholine
Betaine
Betaine
CHDH
BADH
Diet
Diet BHMT DMG
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exposed to hypertonic solutions, by replacing inorganic salts [67, 78, 98]. The intracellular 
concentration of betaine is therefore believed to be much higher than the extracellular 
concentration [99]. The osmoprotective role of betaine is especially important in the renal 
medullary cells, which is frequently exposed to solutions with high salinity [100, 101]. The 
accumulation of betaine occurs via the betaine/γ-aminobutyric acid transporter (BGT1), 
originally identified in the kidneys, where it is located in the basolateral plasma membrane of 
the medullary epithelial cells, and has since been reported to be expressed in many tissues 
[102, 103]. The betaine transporter BGT1 is osmoregulated, and as a response to hypertonic 
stress, the transcription of the BGT1 gene is activated, followed by increased synthesis and 
recruitment of the transport protein to the plasma membrane. This allows betaine to rapidly 
accumulate in the cells and compensate cell shrinkage by the retention of water [103]. When 
the cells are no longer exposed to hypertonic stress, betaine is rapidly removed by an increase 
in efflux trough specific pathways, while the influx through BGT1 is reduced [101]. The 
osmoprotective role of betaine also includes its ability to protect intracellular enzymes and 
proteins against osmotic stress and higher temperatures, by enhancing protein stability, which 
are of great importance in the renal medullary cells, where betaine have been reported to 
counteract the denaturing effect of urea [78].  
 
1.7.4 Betaine and lipid metabolism 
 
Dyslipidemia is disturbance in the lipid metabolism, which is characterized by low serum 
HDL-cholesterol, elevated plasma TG levels, referred to as hypertriglyceridemia, and 
elevated plasma LDL-cholesterol levels [104], referred to as hypercholesterolemia [15]. 
Dyslipidemia are together with insulin resistance and hypertension among the characteristic 
features of the metabolic syndrome often observed in obese subjects, and also a risk factor for 
CVD [105]. 
 
Betaine supplementation (normally 3-6 g/d) among healthy individuals is believed to 
affect the lipid metabolism in the liver, which is the major site of lipid metabolism in the body 
[106, 107]. The hepatic synthesis and secretion of VLDL particles are essential for the 
transport and delivery of triacylglycerols (TGs) and cholesterol esters from the liver to extra 
hepatic tissues throughout the body via the circulation [108]. The VLDL particles are 
especially rich in TGs [109], which are being hydrolyzed by the activity of lipoprotein lipases 
when arriving at the target cells, leading to fatty acid and glycerol release and the subsequent 
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conversion of the VLDLs to cholesterol ester-rich LDL particles [15, 107]. The LDL particles 
then deliver the remaining cholesterol to the peripheral tissues. In contrast high-density 
lipoproteins (HDLs) are responsible for the transport of cholesterol from extra hepatic tissues 
back to the liver [108], known as the reverse cholesterol transport.  
 
 The hepatic ability to synthesize lipoproteins depends on the function of 
apolipoproteins, which are structural proteins with lipid-binding properties, where 
apolipoprotein B (Apo B) and apolipoprotein A1 (Apo A1) are needed in order to synthesize 
VLDL and HDL particles, respectively [107, 110, 111]. Formation of the mature VLDL 
particle takes place in the rough endoplasmatic reticulum membrane, and involves the 
association of Apo B with a TG droplet, which is subsequently encapsulated by a monolayer 
of phospholipids [109, 110, 112]. The outer monolayer of VLDL particles consist mainly of 
the phospholipid PC and the apolipoprotein Apo B [110]. In the liver, formation of PC is 
formed either through the phosphatidylethanolamine (PE) methylation pathway, with SAM as 
a methyl donor [107], or from free choline [113], and is assumed to play an important role in 
hepatic VLDL synthesis and secretion [95, 109, 114].  
 
Because betaine is used to form methionine, which is subsequently converted to SAM, 
betaine supplementation (4-6 g/d) among healthy individuals is suggested to increase the 
SAM/S-adenosylhomocysteine (SAH) ratio, which further leads to enhanced PC synthesis 
[106, 107]. In this manner, betaine is hypothesized to affect the lipid metabolism in the liver 
by increasing the VLDL secretion through an increase in PC synthesis, as shown in Figure 3, 
which further leads to increased TG and LDL-cholesterol levels in plasma, while HDL-
cholesterol levels remains unaffected [106]. Furthermore, betaine supplementation together 
with methionine restriction in rats have been reported to induce the transcription of hepatic 
BHMT mRNA, compared to methionine restriction alone, followed by an increase in the 
transcription of Apo B mRNA, which resulted in increased VLDL secretion and a reduction 
in liver TG concentrations [115]. 
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Figure 3: Proposed mechanism of action for the association between betaine and lipid 
metabolism in the liver. Abbreviations: Betaine Ald, Betaine aldehyde; DMG, dimethylglycine; Hcy, 
homocysteine; BHMT, betaine-homocysteine methyltransferase; Met, Methionine; SAM, S-
Adenosylmethionine; SAH, S-Adenosylhomocysteine; PE, phosphatidylethanolamine; PC, 
phosphatidylcholine; VLDL, Very-low density lipoprotein. 
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2.0 Aims 
 
2.1 Overall aim 
 
The overall aim was to investigate the association of reported dietary betaine intake with 
circulating levels of metabolites along the choline oxidation pathway and serum levels of lipid 
related parameters in patients with SAP. 
 
2.2 Specific aims 
 
1. To examine the relationship between dietary intake of betaine and circulating levels of 
choline, betaine, and related one-carbon metabolites. 
 
2. To explore the association between dietary intake of betaine and serum levels of 
parameters related to lipid metabolism. 
 
3. A secondary aim was to evaluate effect modification by folate status and statin treatment 
on the association between dietary intake of betaine and lipid metabolism. 
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3.0 Materials and methods 
 
3.1 Study design and population 
 
The participants included in this study represent a subpopulation of patients from The 
Western Norway B Vitamin Intervention Trial (WENBIT). WENBIT was a prospective, 
randomized, double-blind, placebo-controlled secondary prevention study of the clinical 
effects of B vitamin treatment in patients who underwent coronary angiography for suspected 
CAD or aortic valve stenosis [54]. Patients diagnosed with cancer, suffering from mental 
illness, abusing alcohol, participating in other studies, or unavailable for the follow-up 
appointment were excluded from participating in the trial. The WENBIT study population 
consisted of 3090 randomized patients, and included both men and women aged >18 years, of 
which 2121 (68.6%) were randomized at Haukeland University Hospital and 969 (31.4 %) at 
Stavanger University Hospital between 1999 and 2004. The flow of randomized patients from 
WENBIT selected for the current study is shown in Figure 4. 
 
 A food frequency questionnaire (FFQ) was handed out to a majority of WENBIT 
participants at the day of recruitment, and was returned by 2484 [116]. Patients with more 
than one blank page (n=19) and those reporting a very low or high total daily energy intake 
(EI) (n=53) (women reporting <3000 and >15000 kJ/d, and men reporting <3300 and >17500 
kJ/d) were excluded. In addition, 10 patients were excluded due to missing blood parameters 
of choline, betaine and DMG. Furthermore, 337 patients (14.0%) with acute coronary 
syndrome, and 39 patients (1.6%) with aortic valve stenosis were excluded from the current 
analysis. Thus, the final study population consisted of 2026 individuals (84.3%) with 
suspected stable angina pectoris (SAP) diagnosed with CAD at baseline coronary 
angiography. 
 
3.2 Ethical statement 
 
All patients gave their written consent to participate. The study was in accordance with the 
principles of the Declaration of Helsinki, and approved by the Regional Committee of 
Medical Research Ethics, the Norwegian Medicines Agency, and the Data Inspectorate. 
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Figure 4: Flow chart of randomized patients from WENBIT to current study population. 
Abbreviations: WENBIT, Western Norway B Vitamin Intervention Trial; HUS, Haukeland University 
Hospital; SUS, Stavanger University Hospital; FFQ, Food Frequency Questionnaire; ACS, Acute 
coronary syndrome; AVS, Aortic valve stenosis; SAP, Stabile Angina Pectoris. 
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3.3 Baseline data 
 
Information about medical history, lifestyle risk factors, and medications were collected from 
each participant at baseline and verified against hospital records [54]. Clinical and 
anthropometric data were collected, measured and assessed by study personnel. Those who 
received medical treatment for hypertension were defined as being hypertensive. Patients 
were defined as having diabetes mellitus DM (type 1 and 2) according to preexisting 
diagnosis, when having a baseline fasting serum glucose ≥7.0 mmol/L or a non-fasting serum 
glucose ≥11.1 mmol/L, or when having a baseline HbA1c ≥ 6.5%. Left ventricular ejection 
fraction (LVEF) (%) was determined by ventriculography or echocardiography, where values 
below 50% were considered to be impaired. The extent of CAD was determined by the use of 
angiography in order to detect the number of stenotic vessels among the patients, which 
ranged between 0 and 3, where 0 was defined as no or non-significant CAD, and 1-3 was 
defined as having a single, double or triple vessel disease, respectively [54]. Estimated 
glomerular filtration rate (eGFR) was determined by use of the Chronic Kidney Disease 
Epidemiology Collaboration creatinine equation [117]. Smoking status was determined by 
self-reported current smoking, including those who quit within the last month, and those with 
plasma cotinine > 85 nmol/L [118]. 
 
3.4 Biochemical analyses 
 
Routine analysis of standard blood parameters was performed directly in fresh blood samples 
at the two university hospitals in Western Norway, while separate blood tubes were stored in 
a biobank at -80°C until analysis. Analyses of choline, betaine, the one-carbon metabolites 
tHcy, DMG, sarcosine, glycine and serine, in addition to cotinine, C-reactive protein and 
glycated hemoglobin (HbA1c) were performed at Bevital A/S, in Bergen, Norway. All 
analyses were based on plasma, except sarcosine (serum) and HbA1c (whole blood). The 
metabolites tHcy, sarcosine, glycine and serine were quantified by gas chromatography, while 
choline, betaine and DMG, including tHcy, were quantified by liquid chromatography. Both 
quantificantion methods were coupled to tandem mass spectrometry. Tina-quant reagent kits, 
obtained from Roche Diagnostics (Mannheim, Gwermany), were used to measure serum Apo 
A1 and Apo B at the Hitachi system (Roche Diagnostics). 
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3.5 Dietary assessment 
 
Habitual dietary intake of the participants was assessed by the use of a FFQ (supplement C), 
developed by the Department of Nutrition at the University of Oslo (Oslo, Norway), and has 
been validated for several nutrients [119-121]. The FFQ was handed out to the patients on the 
day of recruitment, and were returned to the study center by mail, or collected one month later 
at the follow-up appointment. The FFQ was used to acquire information on the patient’s 
habitual food intake during the recent year, and included a total of 169 food items. The food 
items were arranged into groups according to Norwegian food-consumption patterns. The 
portion sizes were given as household measures, such as pieces or slices. The options for 
frequency of consumption were per day, week or month, depending on the food items in the 
question. Average daily intake was used for the analyses. Daily energy and nutrient intake 
reported in the FFQ was estimated using a database and software system developed at the 
Institute for Nutrition Research at the University of Oslo (Kostberegningssystem, version 3.2; 
University of Oslo, Norway). The food database is mainly based on the official Norwegian 
Food Table (1995), which is continuously updated! [121].! Dietary betaine intake was 
calculated using values from the United States Department of Agriculture (USDA) database 
for the choline content of common foods, release two [86]. 
 
3.6 Statistical analysis 
 
To test for normality of variance among dietary data, Kolmogorov-Smirnov´s test and 
Shapiro-Wilk´s test was used. Baseline data were presented as medians (25th, 75th percentiles) 
for continuous variables, using the Tukey´s Hinges method, and n (%) for dichotomous 
variables. Significance value for trend was calculated by using unadjusted linear regression 
for continuous variables and unadjusted logistic regression for dichotomous variables. 
Correlation analyses were performed using Spearman´s rank correlation coefficient, expressed 
as r. Adjustments for age (continuous), gender (dichotomous), total daily EI (continuous) and 
statin use (dichotomous), were made through partial Spearman correlation analyses. Multiple 
linear regression analyses were used to study associations between quartiles of betaine intake 
and serum lipid levels in a multivariate method adjusted for age, gender, body mass index 
(BMI) (continuous), total EI, smoking (dichotomous), diabetes (dichotomous), and statin 
treatment. Furthermore, to check for non-linear associations analyses were repeated with each 
of the three upper quartiles of betaine intake represented as dummy variables in the models. 
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To further evaluate potential tail effects, the association of particular high betaine intake, i.e., 
the upper decile, was examined in the same models. Because folate status as well as statin 
treatment theoretically might influence the effect of betaine intake on lipid metabolism, we 
finally evaluated the potential effect modification by these two parameters. The analyses 
focusing on a particular high betaine intake were therefore repeated by dividing the 
population in two according to median serum folate levels or treatment with cholesterol 
lowering statins. All probability values were two-tailed, and P-values <0.05 were considered 
statistically significant. Statistical analyses were performed using IBM SPSS version 21 (IBM 
Corp. Released 2012. IBM SPSS Statistics for Windows, Version 21.0. Armonk, NY: IBM 
Corp.). 
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4.0 Results 
 
4.1 Baseline clinical characteristics  
 
Clinical characteristics at baseline of 2026 participants by quartiles of dietary betaine intake 
are presented in Table 2. Median (25th, 75th percentile) age was 62 (55, 79) years and 80.4% 
of the participants were men. Median BMI was 26.5 (24.5, 28.7) kg/m2. A previous acute MI 
was reported in 43.6%, percutaneous coronary intervention in 22.8% and coronary artery 
bypass graft surgery in 14.3% of the participants. A total of 31.0% were diagnosed with DM, 
and 47.8% received treatment for hypertension, while 29.8% were current smokers. A 
minority of the participants (10.1%) was considered to have an impaired LVEF. At coronary 
angiography 11.3% had non-significant CAD, while 28.5% had a single-, 27.3% double-, and 
32.8% triple vessel disease. The majority of the participants received medical treatment with 
acetylsalicylic acid (83.9%), statins (79.2%) and β-blockers (75.4%).  
 
 Those with the highest intake of betaine were younger (p<0.001), more likely to be 
males (p<0.001), had a lower BMI (p=0.04), were less likely to be hypertensive (p=0.002), to 
have impaired LVEF (p=0.03), and to have non-significant CAD (p=0.03), and more likely to 
receive treatment with acetylsalicylic acid (p=0.001), compared to those with a low intake. 
Furthermore, higher intakes were associated with higher estimated glomerular filtration rate 
(p<0.001). 
 
Table 2: Baseline clinical characteristics of participants with stable angina pectoris by quartiles of betaine intake (n=2026)1 
 Quartiles of betaine intake  
      
 1 2 3 4 P for trend2 
Betaine (mg) 86.1 (72.7, 96.7)3 119 (112, 127) 148 (142, 159) 198 (180, 226)  
Age (y) 65.0 (58.0, 72.0) 62.0 (56.0, 70.0) 61.0 (55.0, 68.0) 59.0 (53.0, 66.0) <0.001 
Gender; male [n (%)] 299 (59.1) 407 (80.6) 445 (87.4) 477 (94.3) <0.001 
Body mass index (kg/m2) 27.0 (24.7, 29.0) 26.5 (24.7, 28.7) 26.2 (24.2, 28.7) 26.2 (24.3, 28.7)   0.04 
Cardiovascular history [n (%)]     
Myocardial infarction 229 (45.2) 224 (44.3) 219 (43.0) 211 (41.7)   0.22 
Percutaneous coronary intervention 131 (25.9) 120 (23.7) 112 (22.0) 98 (19.3)   0.89 
Coronary artery bypass graft surgery 86 (17.0) 80 (15.8) 64 (12.6) 59 (11.6)   0.85 
Risk factors [n (%)]      
Diabetes mellitus4 152 (0.30) 155 (0.31) 159 (0.31) 162 (0.32)   0.48 
Hypertension5 276 (54.5) 231 (45.7) 238 (46.7) 223 (44.1)   0.002 
Current smoker6 141 (27.8) 150 (29.7) 160 (31.4) 154 (30.4)   0.30 
Extent of CAD [n (%)]      
LVEF< 50% 55 (10.8) 62 (12.3) 51 (10.0) 37 (7.3)   0.03 
No ore non-significant CAD 76 (15.0) 53 (10.5) 38 (7.4) 58 (11.4)   0.03 
One-vessel disease 136 (26.9) 143 (28.3) 152 (29.8) 147 (29.0)   0.37 
Two-vessel disease 127 (25.1) 141 (27.9) 141 (27.7) 145 (28.6)   0.24 
Three-vessel disease 166 (32.8) 167 (33.1) 178 (35.0) 154 (30.4)   0.58 
Medication before baseline coronary angiography [n (%)]    
Acetylsalicylic acid 396 (78.2) 425 (84.1) 447 (87.8) 431 (85.2)   0.001 
Statin treatment 396 (76.9) 402 (79.6) 413 (81.1) 393 (77.6)   0.98 
Beta-blockers 384 (75.9) 379 (75.0) 376 (73.9) 389 (76.9)   0.84 
Glucose homeostasis, inflammation and renal function    
Glucose (mmol/L) 5.6 (5.1, 6.6) 5.6 (5.1, 6.5) 5.6 (5.1, 6.6) 5.6 (5.1, 6.5)   0.75 
HbA1c (%) 5.8 (5.1, 6.6) 5.8 (5.1, 6.5) 5.8 (5.1, 6.6) 5.9 (5.1, 6.6)   0.62 
C-reactive protein (mg/L) 1.73 (0.87, 3.24) 1.77 (0.85, 3.48) 1.61 (0.83, 3.12) 1.51 (0.75, 2.81)   0.61 
eGFR (mL/min) 89.0 (78.0, 97.0) 91.0 (81.0, 99.0) 93.0 (83.0, 101.0) 95.0 (86.0, 102.0) <0.001 
1 n=506, 505, 509 and 506 in quartiles 1 – 4, respectively. 
2 Calculated using linear and logistic regression for continuous and dichotomous variables, respectively. 
3 Median (25th, 75th percentile) for all such values 
4 Based on self-report, HbA1c ≥ 6.5 %, fasting glucose level ≥ 7.0 mmol/L and nonfasting glucose level  ≥11.1 mmol/L. 
5 Patients receiving medical treatment for hypertension. 
6 Based on self-report, stopped smoking < 1 month ago, and cotinine levels > 85 nmol/L. 
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4.2 Daily dietary intake  
 
Daily dietary intakes among the 2026 participants are presented in Table 3. Median (25th, 75th percentile) dietary betaine intake in the 
cohort was 134 (104, 168) mg/d. Increasing intakes of betaine were associated with a higher total energy intake, and also with higher 
intakes of carbohydrate, dietary fiber (p<0.001 for both) and polyunsaturated fat (%TE) (p=0.001). A high betaine intake was however 
inversely associated with intake of saturated fat (%TE), monounsaturated fat (%TE) and protein (%TE) (all p<0.001). 
 
 
Table 3: Daily dietary intake by quartiles of betaine intake (n=2026)1 
 Quartiles of betaine intake  
      
 1 2 3 4 P for trend2 
Energy (kJ) 6134 (5045, 7438)3 7890 (6876, 9041) 9099 (7978, 10347) 11032 (9764, 12895) <0.001 
Carbohydrates (%TE)4 49.7 (44.9, 54.0) 49.1 (45.3, 53.1) 49.8 (45.5, 53.9)  50.5 (46.4, 54.6) <0.001 
Dietary fiber (%TE) 49.7 (44.9, 54.0) 49.1 (45.3, 53.1) 49.8 (45.5, 53.9) 50.5 (46.4, 54.6) <0.001 
Total fat (%TE) 31.2 (27.3, 35.0) 32.1 (28.2, 35.7) 31.2 (28.0, 34.9) 30.7 (27.6, 34.4)   0.13 
Saturated fat (%TE) 11.6 (9.9, 13.3) 11.7 (10.2, 13.3) 11.3 (9.6, 13.1) 11.1 (9.5, 12.7) <0.001 
Monounsaturated fat (%TE) 10.1 (8.7, 11.6) 10.4 (8.9, 11.6) 10.0 (8.9, 11.3) 9.9 (8.7, 11.0) <0.001 
Polyunsaturated fat (%TE) 6.4 (5.4, 8.0) 6.9 (5.7, 8.3) 6.8 (5.7, 8.3) 7.0 (5.9, 8.5)   0.001 
Total proteins (%TE) 17.4 (15.6, 19.2) 16.7 (15.3, 18.4) 16.8 (15.2, 18.5) 16.2 (14.9, 17.8) <0.001 
Alcohol (%TE) 0.70 (<0.00, 2.80) 1.10 (<0.00, 2.80) 1.10 (0.10, 3.10) 1.10 (0.10, 2.80)   0.29 
1 n=506, 505, 509 and 506 for quartiles 1 – 4, respectively. 
2 Calculated using linear regression for continuous variables. 
3 Median (25th, 75th percentile) for all such values. 
4 Percent of total energy intake. 
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4.3 Baseline blood parameters 
 
Circulating levels of parameters related to choline oxidation and lipid metabolism among the participants are presented in Table 4. Higher 
betaine intakes were associated with lower plasma tHcy (p=0.001), glycine (p=0.03) and folate (p<0.001), and with higher plasma betaine 
(p<0.001), betaine-to-choline ratio (p<0.001), and serum sarcosine (p<0.001). Furthermore, betaine intake was associated with lower serum 
total cholesterol (p=0.009), LDL-cholesterol (p=0.04), HDL-cholesterol (p<0.001), Apo B (p=0.049) and Apo A1 (p=0.001). 
 
Table 4: Circulating levels of parameters related to choline and lipid metabolism of by quartiles of betaine intake (n=2026)1 
 Quartiles of betaine intake  
      
 1 2 3 4 P for trend2 
Parameters related to the choline and one-carbon metabolism 
Total homocysteine (µmol/L) 10.6 (8.7, 12.9)3 10.2 (8.7, 12.3) 10.3 (8.7, 12.1) 9.9 (8.5, 11.8)   0.001 
Choline (µmol/L)  9.4 (8.1, 11.2) 9.6 (8.1, 11.3) 9.6 (8.3, 11.2) 9.5 (8.0, 11.4)   0.82 
Betaine (µmol/L) 36.2 (29.8, 45.7) 37.8 (32.2, 46.9) 40.3 (33.3, 48.7) 41.4 (34.9, 49.8) <0.001 
Betaine-to-choline ratio 3.84 (3.16, 4.68) 4.00 (3.35, 4.70) 4.26 (3.50, 5.0) 4.37 (3.64, 5.2) <0.001 
Dimethyl glycine (µmol/L) 3.76 (3.09, 4.72) 3.98 (3.26, 4.91) 4.08 (3.40, 5.0) 4.03 (3.33, 4.74)   0.26 
Sarcosine (µmol/L 1.39 (1.13, 1.80) 1.45 (1.14, 1.79) 1.53 (1.25, 1.94) 1.55 (1.27, 1.93) <0.001 
Serine (µmol/L 93.9 (80.8, 108) 93.1 (80.6, 104) 93.9 (83.2, 108) 93.5 (80.7, 107)   0.73 
Glycine (µmol/L 200 (174, 239) 195 (173, 223) 198 (173, 229) 198 (176, 226)   0.03 
Folate (nmol/L) 10.1 (7.2, 15.0) 10.0 (7.5, 15.2) 9.9 (7.14, 13.9) 9.9 (7.4, 13.6) <0.001 
Parameters related to lipid metabolism 
Total cholesterol (mmol/L) 5.0   (4.40, 5.8) 4.90 (4.30, 5.60) 4.80 (4.20, 5.5) 4.70 (4.10, 5.6)   0.01 
LDL-cholesterol (mmol/L) 2.98 (2.43, 3.70) 2.88 (2.40, 3.60) 2.89 (2.84, 3.50) 2.80 (2.20, 3.50)   0.04 
HDL-cholesterol (mmol/L) 1.28 (1.01, 1.50) 1.20 (1.00, 1.45) 1.20 (1.00, 1.40) 1.20 (1.00, 1.40) <0.001 
Triacylglycerol (mmol/L) 1.49 (1.10, 2.09) 1.55 (1.12, 2.27) 1.57 (1.10, 2.17) 1.55 (1.10, 2.28)   0.34 
Apo B (g/L) 0.86 (0.71, 1.03) 0.85 (0.73, 1.01) 0.84 (0.73, 0.99) 0.83 (0.68, 1.02)   0.049 
Apo A1 (g/L) 1.29 (1.11, 1.49) 1.25 (1.11, 1.43) 1.25 (1.11, 1.43) 1.26 (1.09, 1.41)   0.001 
1 n=506, 505, 509 and 506 in quartiles 1 – 4, respectively. 
2 Calculated using linear regression for continuous variables. 
3 Median (25th, 75th percentile) for all such values. 
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4.4 Dietary betaine intake in association with plasma choline metabolites 
 
Spearman correlation analyses were used to explore the relationship between dietary betaine 
intake and circulating levels of metabolites along the choline oxidation pathway, including 
choline, betaine, tHcy, DMG, sarcosine, glycine and serine. In unadjusted analyses, betaine 
intake was positively associated with plasma betaine (r=0.17, p<0.001) and DMG (r=0.06, 
p=0.006) and with serum sarcosine (r=0.12, p<0.001) and inversely associated with plasma 
tHcy (r=-0.09, p<0.001). There were no associations between dietary betaine intake and 
concentrations of choline, glycine and serine in plasma. The association between betaine 
intake and plasma betaine was attenuated by adjusting for age, gender, total EI and statin use 
(r=0.10, p<0.001). Otherwise, none of the other associations were appreciably affected after 
multivariate adjustment (Table 5).  
 
Table 5: Spearman correlations between dietary betaine intake and circulating levels of 
metabolites related to the choline oxidation pathway. 
 Unadjusted Adjusted1 
 Coefficient P-value Coefficient P-value 
     
Betaine   0.17 <0.001   0.10 <0.001 
Choline   0.004 0.87   0.01 0.68 
Total homocysteine - 0.09 <0.001 - 0.09 <0.001 
DMG   0.06 0.006   0.06 0.006 
Sarcosine   0.12 <0.001   0.07 0.001 
Glycine - 0.02 0.45   0.03 0.21 
Serine   0.002 0.93   0.03 0.23 
1 
Adjusted for age, gender, total energy intake and statin use.  
 
 
Because folate and betaine metabolisms converge at the point of Hcy in the one-carbon 
metabolism, serum folate status is believed to affect the flux of betaine through BHMT, and 
thereby influence the plasma betaine levels [122]. Spearman correlation analysis was thus 
used to investigate the association between betaine and folate in plasma. The results revealed 
a significant positive association in crude analysis (r=0.15, p<0.001), which was not 
attenuated after adjusting for age, gender, and statin use (r=0.17, p<0.001). 
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4.5 Dietary betaine intake in association with lipid related parameters in plasma 
 
The relationships between reported dietary betaine intake and serum levels of parameters 
related to lipid metabolism, including total cholesterol, LDL-cholesterol, HDL-cholesterol, 
TGs, Apo A1 and Apo B were investigated by using multiple linear regression. We first 
evaluated a simple model adjusted for age and gender followed by a more extensive 
multivariate model. Because these models provided similar results we only present the results 
of the multivariate models (Table 6). 
 
Table 6: Association between quartiles of betaine intake with lipid related parameters in serum 
assessed by multiple linear regression (n=2026). 
 Coefficient1 Standard error P-value 
    
Total cholesterol    
Quartiles of betaine intake - 0.03   0.30   0.24 
Age (years) - 0.12   0.003 <0.001 
Male gender - 0.29   0.06 <0.001 
BMI (kg/m2)   0.02   0.01   0.01 
Energy intake (kJ/day) <0.001 <0.001   0.61 
Current Smoking2   0.04   0.05   0.50 
Statins - 1.29   0.06 <0.001 
Diabetes3 - 0.12   0.05   0.02 
    
LDL-cholesterol    
Quartiles of betaine intake - 0.02   0.02   0.33 
Age (years) - 0.01   0.002 <0.001 
Male gender - 0.11   0.05   0.03 
BMI (kg/m2)   0.02   0.01   0.01 
Energy intake (kJ/day) <0.001 <0.001   0.26 
Current Smoking   0.02   0.05   0.65 
Statins - 1.24   0.05 <0.001 
Diabetes - 0.18   0.04 <0.001 
    
HDL-cholesterol    
Quartiles of betaine intake - 0.004   0.01   0.61 
Age (years)   0.004   0.001 <0.001 
Male gender - 0.22   0.02 <0.001 
BMI (kg/m2) - 0.02   0.002 <0.001 
Energy intake (kJ/day) <0.001 <0.001   0.18 
Current Smoking - 0.04   0.02   0.02 
Statins - 0.003   0.02   0.87 
Diabetes - 0.02   0.02   0.18 
    
Triacylglycerol    
Quartiles of betaine intake - 0.02   0.03   0.48 
Age (years) - 0.02   0.003 <0.001 
Male gender   0.14   0.07   0.04 
BMI (kg/m2)   0.07   0.01 <0.001 
Energy intake (kJ/day) <0.001 <0.001   0.52 
Current Smoking   0.08   0.06   0.18 
Statins - 0.16   0.06   0.01 
Diabetes   0.18   0.06   0.001 
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Apo A1    
Quartiles of betaine intake - 0.002   0.01   0.79 
Age (years)   0.002   0.001 <0.001 
Male gender - 0.15   0.01 <0.001 
BMI (kg/m2) - 0.01   0.001 <0.001 
Energy intake (kJ/day) - 0.01 <0.001   0.31 
Current Smoking - 0.01   0.01   0.41 
Statins   0.00   0.01   0.99 
Diabetes - 0.03   0.01   0.01 
    
Apo B    
Quartiles of betaine intake - 0.01   0.01   0.24 
Age (years) - 0.003   0.001 <0.001 
Male gender - 0.01   0.01   0.38 
BMI (kg/m2)   0.01   0.001 <0.001 
Energy intake (kJ/day) <0.001 <0.001   0.35 
Current Smoking   0.02   0.01   0.09 
Statins - 0.25   0.01 <0.001 
Diabetes - 0.02   0.01   0.04 
1 Beta unstandardized coefficient 
2 Based on self-report, stopped smoking < 1 month ago, and cotinine levels >85 nmol/L. 
3 Based on self-report, HbA1c ≥6.5 %, fasting glucose level ≥7.0 mmol/L and nonfasting glucose level ≥11.1 mmol/L 
 
 
Overall, no significant associations were revealed across quartiles of betaine intake with any 
of the parameters of lipid metabolism in the total study cohort. Because folate status as well 
as statin treatment theoretically might influence the effect of betaine intake on lipid 
metabolism, we finally evaluated the potential effect modification by these two parameters.  
 
 
4.5.1 Dietary betaine intake in association with lipid related parameters in subgroups 
 
Since serum folate status may influence plasma betaine levels, it may also influence the 
association between dietary betaine intake and lipid related parameters in plasma. We 
therefore performed multiple linear regression analysis in strata of below and above median 
serum folate (Table 7). Results revealed no significant associations in strata of below and 
above median serum folate. 
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Table 7: Association between quartiles of betaine intake with lipid related parameters in serum 
in patients with either low (<median) or high (≥median) serum folate concentrations assessed 
by multiple linear regression1. 
 Low serum folate2  High serum folate3 
 Coefficients4 Std. error P value  Coefficients Std. error P value 
        
Total cholesterol - 0.04 0.04 0.38  - 0.04 0.04 0.37 
        
LDL-cholesterol - 0.02 0.04 0.66  - 0.03 0.03 0.32 
        
HDL-cholesterol - 0.02 0.01 0.20    0.02 0.01 0.86 
        
Triacylglycerol - 0.01 0.04 0.84  - 0.04 0.05 0.48 
        
Apo A1 - 0.01 0.01 0.56  - 0.001 0.01 0.93 
        
Apo B - 0.01 0.01 0.30  - 0.01 0.01 0.54 
1 Adjusted for age, gender, BMI, total energy intake, diabetes, current smoking and statin treatment. 
2 Serum folate levels < median (9.98 nmol/L) 
3 Serum folate levels ≥ median (9.98 nmol/L) 
4 Beta unstandarized coefficients. 
 
 
The majority (79.2%) of the participants in the present study received medical treatment with 
statins. Statins are lipid modifying drugs that lowers plasma total cholesterol levels by 
inhibition of hepatic cholesterol synthesis, and by enhanced uptake of plasma LDL-
cholesterol into the liver [123], and may thus influence the association between betaine intake 
and lipid related parameters in plasma.  Multiple linear regression analysis was therefore 
performed in strata of non-users and users of statins (Table 8). 
 
 
Table 8: Association between quartiles of betaine intake and lipid related parameters in serum 
in patients without and with statin treatment assessed by multiple linear regression1 
 No statin treatment  Statin treatment 
 Coefficients2 Std. error P value  Coefficients Std. error P value 
        
Total cholesterol - 0.07 0.07   0.32   - 0.06 0.03   0.06 
        
LDL-cholesterol   0.06 0.06   0.30  - 0.04 0.03   0.09 
        
HDL-cholesterol   0.02 0.02   0.39  - 0.012 0.009   0.21 
        
Triacylglycerol - 0.04 0.06   0.51  - 0.016  0.04   0.64 
        
Apo A1   0.02 0.02   0.25  - 0.008  0.01   0.29 
        
Apo B   0.014 0.01   0.35  - 0.012  0.006   0.06 
1 Adjusted for age, gender, body mass index, total energy intake, diabetes and current smoking. 
2 Beta unstandarized coefficients. 
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Overall, there were no significant associations between dietary betaine intake and parameters 
related to lipid metabolism in plasma, neither in the total population, nor when stratifying by 
median folate status or when stratifying by statin treatment. A similar finding was revealed 
when using the second, third and fourth quartile of betaine intake as dummy variables.  
 
4.5.2 Dietary betaine intake above the 90th percentile in association with lipid related 
parameters in the total cohort and in subgroups 
 
Furthermore, in order to investigate whether there still may have been a tail effect illustrating 
an association between a particular high betaine intake and levels of lipid related parameters 
in plasma, we compared the upper decile of dietary betaine intake to the remaining cohort, 
where the cut off value was 207.76 mg/d, when performing multiple linear regression 
analysis (Table 9). 
 
Table 9: The association between particular high betaine intake (≥ 90th percentile) 
with lipid related parameters (n=202)1 
 Coefficient3 Standard error P-value 
    
Total cholesterol - 0.11 0.09 0.22 
    
LDL-cholesterol - 0.14 0.07 0.052 
    
HDL-cholesterol   0.06 0.03 0.02 
    
Triacylglycerol - 0.13 0.09 0.16 
    
Apo A1   0.01 0.02 0.71 
    
Apo B - 0.04 0.02 0.02 
1 Adjusted for age, gender, body mass index, total energy intake, diebates, current smoking and statin treatment. 
2 Beta unstandardized coefficient. 
 
 
Results revealed a significant positive association between particular high betaine intake and 
HDL-cholesterol (β=0.06, p=0.02) and an inverse association with Apo B (β=-0.04, p=0.02). 
 
Based on these observations we performed similar multiple linear regression analyses in 
strata of below and above median serum folate (Table 10). 
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Table 10: The association between particular high betaine intake (≥ 90th percentile) with lipid 
related parameters in patients with either low (<median) or high (≥ median) serum folate 
assessed by multiple linear regression (n=202)1 
 Low serum folate1  High serum folate2 
 Coefficients3 Std. error P value  Coefficients Std. error P value 
        
Total cholesterol - 0.11 0.11 0.36  - 0.12 0.13 0.37 
        
LDL-cholesterol - 0.14 0.10 0.18  - 0.14 0.10 0.08 
        
HDL-cholesterol   0.03 0.04 0.49    0.09 0.04 0.02 
        
Triacylglycerol - 0.05 0.11 0.65  - 0.23 0.16 0.15 
        
Apo A1 - 0.01 0.03 0.72    0.02 0.03 0.50 
        
Apo B - 0.03 0.03 0.23  - 0.05 0.03 0.03 
1 Adjusted for age, gender, body mass index, total energy intake, diabetes, current smoking and statin treatment.  
2 Serum folate levels < median (9.98 nmol/L). 
3 Serum folate levels ≥ median (9.98 nmol/L). 
4 Beta unstandarized coefficients. 
 
 
The results demonstrated no significant associations among those with low serum folate, 
while a significant positive association for a particular high betaine intake with HDL-
cholesterol (β=0.06, p=0.02) and a significant inverse association with Apo B (β=-0.04, 
p=0.02) were observed among those with high serum folate.  
 
We further evaluated the effect of particular high betaine intake and lipid levels according to 
statin treatment (Table 11).  
 
Table 11: Association between particular high betaine intake (≥ 90th percentile) and lipid 
related parameters in patients without and with statin treatment assessed by multiple linear 
regression (n=202)1. 
 No statin treatment  Statin treatment 
 Coefficients2 Std. error P value  Coefficients Std. error P value 
        
Total cholesterol - 0.02 0.20 0.93  - 0.14 0.10 0.14 
        
LDL-cholesterol - 0.02 0.18 0.91  - 0.18 0.08 0.02 
        
HDL-cholesterol   0.10 0.06 0.11    0.05 0.03 0.06 
        
Triacylglycerol - 0.20 0.19 0.56  - 0.14 0.11 0.24 
        
Apo A1   0.05 0.04 0.25  - 0.01 0.02 0.81 
        
Apo B - 0.02 0.04 0.73  - 0.05 0.02 0.01 
1 Adjusted for age, gender, body mass index, total energy intake, diabetes, current smoking, statin treatment.  
2 Beta unstandarized coefficients. 
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Results revealed no significant or tendency towards such an association between having a 
particular high dietary betaine intake and lipid parameters among those who were not treated 
with statins. However, significantly lower LDL-cholesterol (β=-0.18, p=0.02) and Apo B 
levels (β=-0.05, p=0.01) were observed among those receiving statins. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
! 37!
5.0 Discussion 
 
Overall, we found weak, yet statistically significant associations between dietary betaine 
intake and plasma levels of some selected metabolites along the choline oxidation pathway, 
including positive associations with betaine, DMG and sarcosine and an inverse association 
with tHcy. We did not find any associations between quartiles of dietary betaine intake and 
lipid-related parameters, despite an association between intake and lipid parameters in 
unadjusted analyses. However, patients having a particular high betaine intake, corresponding 
to the upper decile, had significantly higher HDL-cholesterol and lower Apo B levels. This 
tail effect was only observed among those with a high folate status. In patients treated with 
statins, a particular high betaine intake was associated with both significantly lower LDL-
cholesterol and Apo B levels. 
 
 
5.1 Methodological discussion 
 
5.1.1 Population and study design 
 
The participants in the present study were part of a large and well-characterized cohort, 
consisting of 3090 randomized patients with angiographically verified CAD as the main 
inclusion criteria. Only patients examined due to suspected SAP were included in the current 
study, the majority receiving lipid lowering statins, and the results are therefore primarily 
valid for such patients. Clinical, anthropometric and dietary data were collected usually just 
after the angiographic procedure for each patient, providing an overview of the outcome and 
the associated characteristics of the patients available for assessment at this specific point in 
time [124]. This study is therefore cross-sectional [125]. The major advantage of a cross-
sectional study design is that it generally is a fast and an un-expensive way to determine the 
amount of individuals with a disease and/or risk factors for the disease [124, 126], and also 
because it is useful to identify associations [127]. However, the limitation of cross-sectional 
studies are related to the fact that they are carried out at a one specific time-point, which give 
rise to the assumption that the associations may not exist outside this given point in time 
[126]. Thus, it is not possible to infer causality [125, 126]. 
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5.1.2 Dietary assessment 
 
Dietary intake can be assessed by using four basic methods, including dietary 24h recalls, 
food records, diet histories and FFQs, which all have their strengths and weaknesses [128]. In 
the present study, dietary intake of the subjects was assessed by use of a self-administered 
FFQ. This dietary assessment method is widely used in nutritional epidemiologic studies, and 
is designed for the assessment of an average diet for longer periods of time, such as weeks, 
months or years, rather than a diet lasting only a few days [129]. The quality of the FFQ 
depends on the responder’s ability to correctly report their diet, and tends to be influenced by 
their present diet and their perception of what constitutes an appropriate diet [128]. Another 
limitation is that the subjects may not be able to accurately report the correct frequency of 
consumption and portion size, and errors related to this issue may occur [129]. These errors 
are part of information biases which may affect the accuracy, and hence the quality of the 
dietary assessment [130]. The FFQ used in the present study included 169 food items, and 
included important sources of betaine, such as bread, breakfast cereals, pasta and root 
vegetables, making it possible to estimate betaine intake. The FFQ has not been validated for 
betaine, but for a number of nutrients, foods and also energy intake [131-133]. Unfortunately, 
no good biomarkers for betaine are currently available, which is why we did not have the 
possibility to explore the validity of the calculated betaine intake estimates this in our study.  
Some actions have been taken to improve the dietary data. Individuals with reported 
total daily EI regarded as unrealistic were excluded. Also, due to resource constraints, the 
current FFQs were not controlled for errors when handed in, and in order to somewhat 
minimize this issue participants reporting >1 blank page were excluded. Due to generally 
poor precision with FFQs, they are better suited for ranking or classifying individuals than 
using absolute values; hence, individuals were either ranked or divided into quartiles when 
performing statistical analyses. Another issue that may affect the accuracy of dietary intake 
assessment is the database used to calculate the nutrient intakes. However, betaine intake was 
estimated by using the USDA database for the choline content in common foods [86], where 
the values in the database has been evaluated and reported to be of good quality [86]. 
Furthermore, when comparing participants who responded with those who did not 
respond to the FFQ, there were certain differences. Non-responders were more likely to be 
women, to be current smokers, to have diabetes, reduced ejection fraction and higher serum 
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total cholesterol, Apo B and C-reactive protein, but less likely to have previously undergone 
a percutaneous coronary intervention [116, 134]. Because the characteristics of the non-
responders were not taken into account in the current analyses, the differences between 
responders and non-responders may bias the results [125, 135, 136].  
5.1.3 Biochemical analysis 
 
The analyses of standard blood laboratory parameters were performed according to routine 
protocols at the two university hospitals in Western Norway. The one-carbon metabolites 
analyzed at Bevital by GC-MS/MS, including tHcy, sarcosine, glycine and serine, had a 
recovery between 79% and 99% [137], while the compounds analyzed by LC-MS/MS, 
including choline, betaine, tHcy and DMG had a recovery ranging from 75% to 123% [138]. 
To assess the assay validation, regression analyses were performed, which showed a linear 
relationship between area ratio and the concentration of the analytes.  
 
5.1.4 Confounding 
 
The general definition of the term confounding can be explained by referring to the 
association between two variables, a specific exposure and an outcome, which are influenced 
by a third variable or group of variables, known as the confounding variable, or the 
confounder, where the confounder are non-casually associated with the exposure and causally 
associated with the outcome [139-141]. In the present study, the exposure is dietary betaine 
intake and the outcome is the metabolites along the choline oxidation pathway and 
parameters related to lipid metabolism. As a consequence of confounding, the strength of the 
association between the exposure and the outcome may be over- or underestimated [139], and 
also lead to a change in the direction of the association [124]. Confounding may thus 
generate biased results, which can be reduced or eliminated by making the appropriate 
statistical adjustments. In nutritional epidemiology, age and gender are among some of the 
variables that are considered to be potentially confounders due to the fact that they are 
correlated with many other factors [140]. Furthermore, because total EI is correlated with 
intake of many nutrients it must be accounted for, especially when analyzing data that are not 
energy adjusted [129]. In addition, statin use may be a confounder due to its lowering effect 
on serum total cholesterol levels [123, 142]. Age, gender, total EI and statin use were thus 
adjusted for when performing partial Spearman´s rank correlations. Additional factors that 
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may have a confounding effect on the association between betaine intake and lipid related 
parameters in plasma are BMI, diabetes and smoking. Hence, these factors were also adjusted 
for when performing multiple linear regression. 
 
5.1.5 Energy adjustment 
 
In the present study, adjustment for total EI was made by using the standard multivariate 
model [129]. When performing Spearman’s rank correlations and multiple linear regressions, 
both betaine and total EI was included simultaneously as independent variables. However, 
there is no general agreement on which approach that accomplishes this most efficiently, and 
several methods currently exist. One alternative approach may be to use the residual method, 
where the nutrient intake of each individual are plotted against their total EI in a linear 
regression model to produce residuals to which a constant is usually added [143]. This or 
other methods could be considered in further analyses. 
 
5.1.6 Statistical analysis 
 
Reported dietary betaine intake among the current participants was not normally distributed. 
Therefore, to explore the associations between dietary intake of betaine and plasma 
metabolites along the choline oxidation pathway Spearman´s rank correlation was used. 
Spearman rank correlation is a non-parametric statistical method which do not require a 
normal distribution [144], and was suitable in the present study where obtained data from all 
participants were ranked prior to analysis [145]. This method measures the strength and 
direction of the association between two variables, while a partial Spearman rank correlation 
allows an adjustment for other covariates [146]. In addition, the Spearman rank correlation is 
also less sensitive to outliers. Although the Spearman correlation coefficient do not infer 
causality, it is useful with regard to discussing probable mechanisms based on the strength 
and direction of the observed association [145, 147].  
Multiple linear regression was applied in order to investigate possible associations 
between dietary betaine intake and parameters related to lipid metabolism. Multiple linear 
regression is a parametric statistical method, which is based on correlation, and is used to 
explore the association between one continuous dependent variable and a number of 
independent variables [146]. In the present study lipid related parameters in plasma were the 
dependent variables, while betaine intake in addition to age, gender, total EI, BMI, diabetes, 
! 41!
current smoking, and statin treatment were the independent variables. When performing a 
multiple linear regression analysis, all the independent variables are included simultaneously, 
where each of their predictive power is being assessed, and allows the investigator to sort out 
the many different features of risk factors and explore how they affect the outcome [141]. In 
addition, stratified analyses may be useful in order to assess effect modification [148, 149]. 
Since folate status is believed to affect plasma betaine levels, and statin treatment is known to 
influence lipid metabolism, the analyses were performed separately in those with serum 
folate below and above median, as well as in non-users and users of statins. However, the 
statistical package used did not allow to test for significant interaction, and the results 
obtained by stratification are therefor only exploratory and should motivate further 
investigations 
 
5.2 Discussion of results 
 
5.2.1 Betaine intake and plasma metabolites of the choline oxidation pathway 
 
In the current cohort median (25th, 75th percentile) dietary betaine intake was 134 (104, 168) 
mg/d, which is similar compared to the estimated intakes in large cohorts in the US and 
Europe, where intakes have been reported to generally range between 100 and 300 mg/d [87-
91]. Most studies on this subject have focused on studying the effect of betaine 
supplementation, and due to a lack of food-composition databases in the previous years, only 
fewer studies have investigated the effect of a habitual dietary intake of betaine. Several 
studies have demonstrated consumption of betaine supplements to lead to an immediate 
increase in plasma betaine concentrations and a decrease in plasma tHcy concentrations, 
occurring in a dose dependent manner [74, 150-157]. Similar results have been obtained after 
ingestion of a betaine-enriched meal [158, 159]. A significant increase in plasma DMG has 
also been reported after betaine consumption in high doses [156, 157, 159]. In agreement 
with the current results, previous studies have also revealed a significant inverse association 
of dietary betaine with plasma tHcy [88, 91, 160].  
The current findings are, however, not directly comparable with studies using 
supplements and betaine-enriched diets, which have a substantially higher betaine content 
(generally 1-6 g) compared to that of an average diet. Thus, it appears that a betaine intake, 
which exceeds that of an average daily diet, produces stronger associations with plasma 
betaine, tHcy and DMG.  
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5.2.2 Betaine intake and plasma levels of lipid related parameters 
 
Few studies have investigated the association of dietary betaine intake and serum levels of 
lipid related parameters, and the reported effects of dietary and supplementary betaine intake 
on lipid metabolism from previous findings during the recent years are conflicting. The 
current findings are in agreement with findings from two cross-sectional studies among 
subjects with ACS attending a lipid clinic [161] and a large cohort of middle aged and elderly 
subjects [162], where plasma betaine was inversely associated with non-HDL-cholesterol and 
TG concentrations,  and positively associated with HDL-cholesterol concentrations. 
However, in a study among healthy subjects [106], and a study among patients with chronic 
renal failure [163], betaine supplementation was associated with elevated LDL-cholesterol 
and TG concentrations, whereas in a study among obese subjects [151], and two studies 
among healthy subjects [156, 159] no significant associations were revealed.  
 
 
5.3 Possible mechanisms 
 
5.3.1 Betaine intake and plasma metabolites of the choline oxidation pathway 
 
Dietary betaine intake was weakly, yet significantly associated with plasma one-carbon 
metabolites. Betaine is rapidly removed from plasma by being distributed into most tissues, 
mainly the liver and kidneys, where it is needed as an osmolyte or methyl donor [152]. Both 
the transport of betaine into tissues through the betaine transporter BGT1, and the 
metabolism of betaine by BHMT is osmoregulated [78, 103], ensuring betaine to be under 
strict metabolic control, which gives rise to inter-individual variability in serum betaine 
[157].  
 
 The observed significant associations with DMG and tHcy in plasma is in 
accordance with betaine being eliminated in the liver and kidney by betaine-dependent 
remethylation of Hcy into methionine, as it is metabolized to DMG, by BHMT [155, 158]. 
Furthermore, the transmethylation pathways of which folate and betaine enters in the one-
carbon metabolism converges at the point of Hcy [75]. Plasma betaine levels have been 
reported to increase with folate supplementation, which may be a result of BHMT being 
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inhibited by 5-mTHF [73]. Moreover, among subjects with low folate status, plasma betaine 
has been reported to be a determinant with an increase in tHcy concentrations [122]. This 
suggests that the 2 transmethylation pathways are interrelated, and it may thus be 
hypothesized that lower circulating levels of folate increases the need for betaine as a methyl 
donor, while higher circulating levels of folate has a betaine sparing effect [73, 164]. Hence, 
we were interested in looking at the association between folate and betaine in plasma in the 
current study population, where a significant positive association was observed. Based on this 
observation, and the observed weak, although significant correlations between betaine intake 
and plasma one-carbon metabolites, it may be assumed that a high folate status leads to a 
lower activity of BHMT, which reduces the flow of betaine through the transmethylation 
pathway in the one-carbon metabolism. This is plausible due to the fact that folate-dependent 
remethylation occurs in most tissues, while betaine-dependent remethylatin is restricted to the 
liver and kidney [150]. Furthermore, adjusting for age, gender, total EI and statin use in the 
present study attenuated the association between betaine intake and plasma betaine, but did 
otherwise not appreciably affect the other associations. 
 
5.3.2 Betaine intake and plasma levels of lipid related parameters 
 
In the current cohort, a higher betaine intake was associated with lower HDL-, LDL- and 
total cholesterol levels, and lower Apo A1 and Apo B levels, when performing unadjusted 
linear regressions. Furthermore, when performing adjusted multiple linear regression 
analyses, no significant associations were observed between quartiles of betaine intake and 
lipid related parameters, neither in the total study population, nor in those with serum folate 
below and above median, or in non-users and users of statins. However, among those in the 
upper decile of betaine intake significantly higher HDL-cholesterol and lower Apo B levels 
were observed, when compared with the rest of the population. Moreover, those having a 
betaine intake corresponding to the upper decile had significantly higher HDL-cholesterol 
and lower Apo B levels. Moreover, in the stratified analyses, those with a betaine intake in 
the upper decile and who also had high serum folate had significantly higher HDL-
cholesterol and lower Apo B levels, while those using statins had lower LDL-cholesterol and 
Apo B levels. 
Results from previous studies with betaine supplements differ from those in the 
current study. High doses of betaine intake have been associated with increased LDL-
cholesterol and TG levels among healthy subjects [106] and among subjects with chronic 
! 44!
renal failure [163]. In the present study, among patients with SAP on conventional medical 
treatment, a particular high dietary intake of betaine was associated with higher HDL-
cholesterol and lower Apo B levels. The flux of betaine through BHMT in the 
transmethylation pathway is believed to be enhanced when betaine is increasingly available 
[157], which also have been previously demonstrated in animals [165-167]. It may thus be 
speculated that high doses of betaine intake affects the lipid metabolism differently compared 
with habitual dietary betaine intake. A possible mechanism linking betaine to the hepatic 
lipid metabolism have previously been hypothesized to be through enhanced methionine 
synthesis and the following increase in the SAM/SAH ratio, which ultimately leads to 
increased VLDL synthesis and secretion [95, 107].  
 
The association between a particular high betaine intake and lipid related parameters 
among those with serum folate above median is interesting. A low folate status has been 
associated with accumulation of lipids in the liver, while less is known about the effect of a 
high folate status [168]. Supplementation with folic acid did not affect the lipid metabolism 
in a study among healthy subjects [106]. However, middle aged and elderly men and women 
had increased plasma betaine levels after receiving folic acid supplements [73], which 
suggests that folate and betaine metabolism may be interrelated. Because both betaine and 
folate is achieved from foods such as grains, cereals and vegetables [82-84, 169], a high 
dietary betaine intake and a high folate status may simply be an indicator of an overall 
healthy diet, which in general is associated with a favorable lipid profile [170, 171], including 
higher HDL-cholesterol levels [172].  
 
Furthermore, other mechanisms might also be involved. 5-mTHF has been reported to 
reduce the flux through BHMT [73] and inhibit GNMT [70], two enzymes believed to be 
involved in lipid metabolism. First, the transcription of BHMT has been reported to be 
associated with co-transcription of Apo B [115], the main apolipoprotein involved in the 
VLDL synthesis in the liver. Second, the flux through BHMT may be involved in the 
transcription of nuclear transcription factor peroxisome proliferator activator receptor alpha 
[173-175], which is an important regulator in lipid metabolism [176].  Third, GNMT activity 
is associated with co-activity of the Nieman Pick CII like protein 2, which is involved in the 
transport of cholesterol from the lysosomes to be incorporated into VLDL or HDL particles 
[177].  
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Previously, circulating betaine has been inversely associated with LDL-cholesterol 
and TG levels and positively associated with HDL-cholesterol among subjects with ACS 
attending a lipid clinic and receiving treatment with statins [161]. Betaine intake was 
inversely associated with circulating LDL-cholesterol and Apo B levels among statin users 
having a particular high betaine intake in the current study. Unpublished data from WENBIT 
shows that statin treatment is associated with higher circulating betaine. This indicates that 
statin treatment might influence betaine synthesis or metabolism and this hypothesis should 
be explored in future studies. 
 
The current observations indicate a change in how lipid metabolism is regulated 
depending on both folate status or statin treatment. However, these analyses have not been 
tested for interaction, and hence, it can not be determined with certainty whether the 
relationship between betaine intake and lipid related parameters in plasma are significantly 
different in strata of serum folate status and statin treatment.  
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6.0 Conclusion 
 
In this cross-sectional study among 2026 patients with angiographically verified SAP, there 
were weak, yet statistically significant associations of habitual dietary intake of betaine with 
plasma metabolites of the choline oxidation pathway, including betaine, tHcy, DMG and 
sarcosine. Those in the upper decile of betaine intake with a high folate status had 
significantly higher plasma HDL-cholesterol and lower Apo B levels, while those using 
statins had significantly lower LDL-cholesterol and Apo B levels. 
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7.0 Future perspectives 
 
The current observations of the association between a particular high betaine intake and lipid 
related parameters in plasma were made in patients with SAP. Further research should thus 
investigate these associations can be reproduced in other cohorts or subgroups in order to 
achieve a broader understanding on the effects of habitual dietary betaine intake on 
circulating levels of lipid related parameters. One appropriate way to study these associations 
into more detail is to perform randomized studies where eg. participants receive a betaine 
diet, compared to a control diet. Furthermore, due to challenges of measuring dietary intake, 
which may further bias the results, future studies should explore possible biomarkers for 
dietary intake of betaine.  
Betaine has been hypothesized to affect the hepatic lipid metabolism through 
mechanisms that ultimately lead to increased VLDL synthesis and secretion. However, this 
was not observed in the present study. Such mechanisms may be studied by using cell culture 
or animal models, followed by measuring metabolites and lipids, as well as genes and/or 
enzymatic activities. 
The association between betaine and lipid metabolism have also been suggested to be 
linked to the activation of the peroxisome-proliferator activated receptor alpha (PPARα). 
PPARα is a nuclear receptor protein, located mainly in the liver, kidney, heart and skeletal 
muscles, regulating the expression of several genes, including many involved in fatty acid 
beta-oxidation, and thus functions as a major regulator of energy homeostasis. In a study 
conducted in Apo E deficient mice, supplementation of betaine reduced hepatic TG content, 
resulting from reversed hypermethylation of the PPARα promoter. Due to limited studies on 
the association between betaine and PPARα, further research on this topic may be useful in 
order to reveal possible underlying mechanisms between betaine and hepatic lipid 
metabolism. 
Betaine is considered to be an important modulator of the one-carbon metabolism, by 
serving as a methyl donor in a transmethylation pathway, where the first step along this 
pathway is catalyzed by BHMT. The availability of betaine is believed to affect the flow 
through BHMT. How to accurately measure this metabolic flow should thus be interesting to 
investigate in future research.  
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HVA SPISER DU?
I dette skjemaet spør vi om dine spisevaner slik de vanligvis er.
Vi er klar over at kostholdet varierer fra dag til dag. Prøv derfor 
så godt du kan å gi et "gjennomsnitt" av dine spisevaner. Ha det
siste året i tankene når du fyller ut skjemaet. Der du er usikker,
anslå svaret.
Skjemaet skal leses av en maskin, og derfor er det viktig at du
setter et tydelig kryss i avmerket rute.
Riktig markering er slik:
Bruk helst bløt blyant. Feil kan da rettes med viskelær.
Kulepenn og svart tusjpenn kan også brukes.
Av hensyn til den maskinelle lesingen pass på at arkene ikke blir brettet.
Alle svar vil bli behandlet strengt fortrolig.
EKSEMPEL PÅ UTFYLLING AV SPØRSMÅL 1.
Kari Nordmann spiser daglig 5 skiver brød og ett
knekkebrød. Hun spiser vanligvis kneippbrød, men i helgene
blir det en del loff. I tillegg spiser hun ett knekkebrød hver
dag. Hun fyller ut første spørsmål slik:
1.HVOR MYE BRØD PLEIER DU Å SPISE?
Legg sammen det du bruker til alle måltider i løpet av en dag.
(1/2 rundstykke = 1 skive, 1 baguett = 5 skiver, 1 ciabatta = 4 skiver)
Fint brød
(loff, baguetter, fine rundstykker o.l.)
Mellomgrovt brød
(lys helkorn, lys kneipp, lyst hj.bakt o.l.)
Grovt brød
(fiberkneipp, mørk kneipp, mørkt hj.bakt o.l.)
Knekkebrød
(kavring, grov skonrok o.l.)
0 1/2 1 2 3 4 5 6 7 8 9 10 11 12+
Antall skiver pr. dag
Sum skiver pr. dag = ____
Antall skiver pr. uke: _______ = ____  Tallet brukes i spørsmål 5.
6
6 x 7 42
2.HVA PLEIER DU Å SMØRE PÅ 
BRØDET?
Merk av både for hverdag og helg, selv
om du bruker det samme.
3.OM DU BRUKER 
FETT PÅ BRØD, HVOR
MYE BRUKER DU?
4.MELK SOM DRIKK
(1 glass = 1,5 dl)
1.HVOR MYE BRØD PLEIER DU Å SPISE?
Legg sammen det du bruker til alle måltider i løpet av en dag.
(1/2 rundstykke = 1 skive, 1 baguett = 5 skiver, 1 ciabatta = 4 skiver)
Fint brød
(loff, baguetter, fine rundstykker o.l.)
Mellomgrovt brød
(lys helkorn, lys kneipp, lyst hj.bakt o.l.)
Grovt brød
(fiberkneipp, mørk kneipp, mørkt hj.bakt o.l.)
Knekkebrød
(kavring, grov skonrok o.l.)
0 1/2 1 2 3 4 5 6 7 8 9 10 11 12+
Antall skiver pr. dag
Sum skiver pr. dag = ____
Antall skiver pr. uke: ____ x 7 = ____. Tallet brukes i spørsmål 5.
Hverdager Lørdager, søndager En porsjonspakning på 12 g
rekker til antall skiver
Bruker ikke
1/2 1 2 3 4 5 6 7 8+
Drikker
sjelden/
ikke
Antall glass pr. dag
1
5
4
3
2
61852
3
Smør   (meierismør)
Bremykt, Smøregod
Brelett
Soft, soyamargarin (pakke, beger)
Solsikke
Oliven
Vita
Olivero
Omega
Soft light
Vita lett
Annen margarin
Helmelk, søt, sur
Lettmelk, søt, sur
Lettmelk, ekstra lett
Skummet melk, søt, sur
61852
5.PÅLEGGSSORTER
Bruk sum skiver pr. uke fra spørsmål 1.
Brun ost, prim
Hvit ost, helfet, 27% fett (Jarlsberg,
Norvegia o.l., smøreost; eske, tube)
Hvit ost, halvfet, 16% fett (Jarlsberg,
Norvegia o.l., smøreost; eske, tube)
Ost med mer enn 27% fett
(kremoster, Normanna, Ridderost)
Leverpostei, vanlig
Leverpostei, mager
Servelat, vanlig
Lett servelat, kalverull,
kokt skinke, okserull o.l.
Salt pølse, spekepølse
(fårepølse, salami o.l.)
Kaviar
Sardiner, sursild, ansjos o.l.
Makrell i tomat, røkt makrell
Laks, ørret
Syltetøy, marmelade, frysetøy
Reker, krabbe
Honning, sirup,
sjokolade-, nøttepålegg
Majones på smørbrød
Grønnsaker som pålegg
(agurk, tomat o.l.)
Frukt som pålegg (banan, eple o.l.)
Salater med majones
(kokt, stekt, eggerøre, omelett)
6.EGG
0
Til antall skiver pr. uke
1/2 1 2-3 4-5 6-7 8-14 15-21 22-28 29-35 36+
0 1/2 1 2-3 4-5 6-7 8-14 15-21 22-28 29-35 36+
0 1/2 1 2-3 4-5 6-7 8-14 15-21 22-28 29-35 36+
0 1/2 1 2-3 4-5 6-7 8-14 15-21 22-28 29-35 36+
0 1/2 1 2-3 4-5 6-7 8-14 15-21 22-28 29-35 36+
0 enn 1 1 3-4 5-6 7 8+2
Mindre Antall pr. uke
4
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8. KAFFE OG TE
(1 kopp kaffe = 1,2 dl    1 kopp te = 2 dl)
7. FROKOSTGRYN, GRØT OG YOGHURT
Svar enten pr. måned eller pr. uke. <1 betyr sjeldnere enn 1 gang.
Melk søt, sur på gryn,
grøt og dessert
Havregryn, kornblandinger
(4-korn, usøtet müsli o.l.)
Cornflakes, puffet ris,
havrenøtter o.l.
Havregrøt
Sukker til frokostgryn, grøt
Yoghurt, naturell, frukt
Lettyoghurt
Go´morgen yoghurt
inkl. müsli
Kaffe, kokt
Kaffe, traktet, filter
Kaffe, pulver (instant)
Kaffe, koffeinfri
Te
Nypete, urtete
Sukker til kaffe
Sukker til te
Fløte til kaffe
Kunstig søtstoff til kaffe eller te
0 1/2 1 2 3
Antall teskjeer eller biter pr. kopp
4+
1/2 1 3-42 5-6
Antall kopper pr. dag
7-8
Drikker
ikke/ikke
daglig 9-10 11+
2-3
Gang pr. måned Gang pr. uke Mengde pr. gang
4-5 6-7 8+1321<10
1 1 1/2 2 3+
1 1 1/2 2 3+
1-2 3-4 5-6 7+
1 2 3-4 5+
1/2 1 1 1/2 2+
1/2 1 1 1/2 2+
1/2 1 1 1/2 2+
3/4 1 2 3+
(dl)
(dl)
(dl)
(ts)
(beger)
(beger)
(beger)
(dl)
5
Taco (med kjøtt og salat)
Pastaretter
Alkoholfritt øl, vørterøl,
lettøl
Kjøttdeigretter (saus eller gryte
med kjøttdeig, lasagne o.l.)
9. ANDRE DRIKKER?
Svar enten pr. måned eller pr. uke.  < 1 betyr sjeldnere enn 1 gang.
Merk at porsjonsenhetene er forskjellige. 1/3 liter tilsvarer en halvflaske øl 
og 2/3 liter tilsvarer en helflaske.
Vann
Appelsinjuice
Annen juice, most, nektar
Saft, solbærsirup
m. sukker
Saft, kunstig søtet
Brus, Cola, Solo o.l.,
med sukker
Brus, Cola, Solo o.l.,
kunstig søtet
Farris, Selters, Soda o.l.
Pilsnerøl
Vin
Brennevin, likør
Kjøttpølse, medisterpølse
Hamburger, karbonader o.l.
Grill- og wienerpølse
Kjøttkaker, medisterkaker,
kjøttpudding
Hamburger-, pølsebrød,
lomper
2
Gang pr. måned
1<10 3 4 5-6 7-8 9+
(kjøttpølse)
(stk)
(pølse)
(stk)
(stk)
(dl)
(stk)
(dl)
Gang pr. måned Gang pr. uke Mengde pr. gang
0 <1 1 2 3 1 2-3 4-5 6-7 8+
(glass)
(glass)
(glass)
(glass)
(glass)
(liter)
(liter)
(liter)
(liter)
(liter)
(glass)
(1 dram
= 4 cl)
1/2 1 2 3 4
1/2 1 2 3 4
1/2 1 2 3 4
1/2 1 2 3 4
1/2 1 2 3 4
1/4 1/3 1/2 2/3 1
1/4 1/3 1/2 2/3 1
1/4 1/3 1/2 2/3 1
1/4 1/3 1/2 2/3 1
1/4 1/3 1/2 2/3 1
1 2 3 4 5
1 2 3 4 5
5+
5+
5+
5+
5+
11/2+
11/2+
11/2+
6+
6+
11/2+
11/2+
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10. MIDDAGSRETTER
Vi spør både om middagsmåltidene og det du spiser til andre måltider. Tell til slutt
sammen antall retter du har merket for og se om summen virker sannsynlig.
En "dl" tilsvarer omtrent mengden i en suppeøse. Med "ss" menes en spiseskje.
Mengde pr. gang
1/2 2/3 1 2+
1 2 3 4 5+
1 2 3 4 5+
1 2 3 4 5+
1 2 3 4 5+
1 2 3 4 5+
1 2 3 4 5+
1 2 3 4 5+
11/2
6
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Pizza (500-600 g)
Koteletter (lam, okse, svin)
Biff (alle typer kjøtt)
Stek (elg, hjort, reinsdyr o.l.)
Stek (lam, okse, svin)
Gryterett med helt kjøtt,
frikassé, fårikål o.l.
Lapskaus, suppelapskaus,
betasuppe
Bacon, stekt flesk
Kylling, høne
Torsk, sei, hyse (kokt)
Leverretter
Fiskekaker, fiskepudding,
fiskeboller
Fiskepinner
Torsk, sei, hyse (stekt, panert)
Sild (fersk, speket, røkt)
Makrell (fersk, røkt)
Laks, ørret (sjø, oppdrett)
Fiskegryte, -grateng, suppe
med fisk
Reker, krabbe
Risgrøt, annen melkegrøt
Pannekaker
Suppe (tomat, blomkål,
ertesuppe o.l.)
Vegetarrett, vegetarpizza
grønnsakgrateng, -pai
Brun/hvit saus
Smeltet margarin, smør
til fisk
Bearnaisesaus o.l.
Majones, remulade
Ketchup
2
Gang pr. måned
(pizza)
(stk)
(stk)
(skive)
(skive)
(dl)
(dl)
(skive)
(stk)
(skive)
(kake)
(stk)
(stk)
(stk)
(filet)
(filet)
(skive)
(dl)
(dl, renset)
(dl)
(stk)
(dl)
(bit/dl)
(dl)
(ss)
(ss)
(ss)
(ss)
Mengde pr. gang
1<10 3 4 5-6 7-8 9+
1/8 1/4 1/2 3/4 1+
21<10 3 4 5-6 7-8 9+
21<10 3 4 5-6 7-8 9+
21<10 3 4 5-6 7-8 9+
1/2 1 1 1/2 2 2 1/2+
1-2 3-4 5-6 7-8 9+
1/4 1/3 1/2 3/4 1+
1 2 3 4 5+
1/2 1 1 1/2 2 3+
1-2 3-4 5-6 7-8 9+
1 2 3 4 5+
1 2 3 4 5+
1 2 3 4 5+
1/2 1 1 1/2 2 2 1/2+
1-2 3-4 5-6 7-8 9+
1-2 3-4 5-6 7-8 9+
1-2 3-4 5-6 7-8 9+
1-2 3-4 5-6 7-8 9+
1-2 3-4 5-6 7-8 9+
1-2 3-4 5-6 7-9 10+
1 2 3 4 5+
1 2 3 4 5+
1 2 3 4 5+
1 2 3 4 5+
1 2 3 4 5+
1-2 3-4 5-6 7-8 9+
1-2 3-4 5-6 7-8 9+
1-2 3-4 5-6 7-8 9+
1-2 3-4 5-6 7-8 9+
1-2 3-4 5-6 7-8 9+
1/2 1 1 1/2 2 2 1/2+
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11. POTETER, RIS, SPAGHETTI, GRØNNSAKER
Svar enten pr. måned eller pr. uke. <1 betyr sjeldnere enn 1 gang.
Disse spørsmålene dreier seg først og fremst om tilbehør til middagsretter, men
spiser du for eksempel en rå gulrot eller salat til lunsj, skal det tas med her. 
0
Gang pr. måned Gang pr. uke Mengde pr. gang
<1 1 2 3 1 2-3 4-5 6-7 8+
Poteter, kokte
Pommes frites, stekte
poteter
Potetmos, -stuing,
gratinerte poteter
Ris
Spaghetti, makaroni,
pasta
Gulrot
Hodekål
Kålrot
Blomkål
Brokkoli
Rosenkål
Grønnkål
Løk
Spinat, andre bladgrønns.
Sopp
Avocado
Paprika
Tomat
Tomatbønner, bønner/linser
Mais
Erter, frosne grønnsak-
blandinger
Salatblandinger
Dressing
Rømme
Hvor mange ganger om dagen spiser du vanligvis
grønnsaker utenom grønnsakene du spiser til middag?
(stk)
(dl)
(dl)
(dl)
(dl)
(stk)
(skalk)
(skive)
(bukett)
(bukett)
(stk)
(dl)
(ss)
(dl)
(stk)
(stk)
(strimmel)
(stk)
(dl)
(ss)
(dl)
(dl)
(ss)
(ss)
1 2 3 4 5+
1 2 3 4 5+
1 2 3 4 5+
1 2 3 4 5+
1 2 3 4 5+
1 2 3 4 5+
1 2 3 4 5+
1 2 3 4 5+
1 2 3 4 5+
1 2 3 4 5+
1 2 3 4 5+
1 2 3 4 5+
1/2 1 2 3 4+
1/2 1 2 3 4+
1-2 3-4 5-6 7-8 9+
1-2 3-4 5-6 7-8 9+
1-2 3-4 5-6 7-8 9+
1-2 3-4 5-6 7-8 9+
1-2 3-4 5-6 7-8 9+
1-2 3-4 5-6 7-8 9+
1-2 3-4 5-6 7-8 9+
1/2 1 1 1/2 2 3+
1/4 1/2 3/4 1 1 1/4 +
1/2 1 1 1/2 2 3+
0 1 2 3 4 5+
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12. TYPE FETT TIL MATLAGING
13. FRUKT
Svar enten pr. måned eller pr. uke. < 1 betyr sjeldnere enn 1 gang.
Hvor mange frukter spiser du vanligvis pr. dag? 0 1 2 3 4 5 6
9
Smør (meierismør)
Bremykt
Melange, Per
Soft-, soyamargarin (pakke, beger)
Solsikke
Oliven
Olivenolje
Soyaolje
Maisolje
Solsikkeolje
Valnøttolje
Andre oljer
Annen margarin
Smør/margarin Oljer
Mengde pr. gang
Eple 0
Appelsin, mandarin,
grapefrukt
Banan
Druer
Eksotisk frukt (kiwi, mango)
Annen frukt (fersken,
pære m.v.)
Jordbær, bringebær
(friske, frosne)
Blåbær
Gang pr. måned Gang pr. uke
<1 1 2 3 1 2-3 4-5 6-7 8+
(stk)
(stk)
(stk)
(klase)
(stk)
(stk)
(dl)
(dl)
1/2 1 2 3+
1/2 1 2 3+
1/2 1 2 3+
1/2 1 2 3+
1/2 1 2 3+
1/2 1 2 3+
1/2 1 2 3+
1/2 1 2 3+
Multer (dl)
1/2 1 2 3+
7 8 9+
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14. DESSERT, KAKER, GODTERI
Svar enten pr. måned eller pr. uke. < 1 betyr sjeldnere enn 1 gang.
Hermetisk frukt, fruktgrøt
Puddinger (sjokolade,
karamell o.l.)
Is (1 dl = 1 pinne = 1
kremmerhus)
Boller, julekake, kringle
Skolebrød, skillingsbolle
Wienerbrød, -kringle o.l.
Smultring, formkake
Vafler
Sjokoladekake, bløtkake,
annen fylt kake
Søt kjeks, kakekjeks
(Cookies, Bixit, Hob Nobs)
Sjokolade (60 g)
Drops, lakris, seigmenn o.l.
Smågodt (1 hg = 100g)
Potetgull (1 pose 100g = 7 dl)
Annen snacks (skruer, crisp,
saltstenger, lettsnacks o.l.)
Peanøtter, andre nøtter
(1 pose 100g = 4 never)
Gang pr. måned Gang pr. uke Mengde pr. gang
0 <1 1 2 3 1 2-3 4-5 6-7 8+
(dl)
(dl)
(dl)
(stk)
(stk)
(stk)
(stk)
(stk)
(stk)
(stk)
(plate)
(plate)
(hg)
(dl)
(dl)
(neve)
1/2 3+21
1/2 3+21
1/2 3+21
1 4+32
1 4+32
1 4+32
1 4+32
1 4+32
1 4+32
1 4+32
1-2 7+5-63-4
1-2 7+5-63-4
1-2 7+5-63-4
1-2 7+5-63-4
1/2 1 1/2+13/4
1/2 3+21
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15. KOSTTILSKUDD (bs = barneskje, ts = teskje)
Tran
Trankapsler
Fiskeoljekapsler
Multipreparater
Sanasol
Biovit
Vitaplex
Kostpluss
Vitamineral
Annet
Jernpreparater
Ferro C
Hemofer
Duroferon
Duretter
Annet
B-vitaminer
C-vitamin
D-vitamin
E-vitamin
Folat (folsyre)
Kalktabletter
Fluortabletter
Annet
Hvis annet, hvilket? ..................................................................
Hvis annet, hvilket? ..................................................................
Hvis annet, hvilket? ..................................................................
Gang pr. uke
6-7
Mengde pr. gang
4-52-31<10
6-74-52-31<10
6-74-52-31<10
6-74-52-31<10
6-74-52-31<10
kapsler
kapsler
bs
bs
tablett
tablett
tablett
tablett
tablett
tablett
tablett
tablett
tablett
tablett
tablett
tablett
tablett
tablett
tablett
tablett
1 ts 1 bs 1 ss
1 2+
1-2 3-4 5-6 7+
1 2 3 4+
1 2 3 4+
1 2 3 4+
1 2 3 4+
1 2 3 4+
1 2 3 4+
1 2 3 4+
1 2 3 4+
1 2 3 4+
1 2 3 4+
1 2 3 4+
1 2 3 4+
1 2 3 4+
1 2 3 4+
1 2 3 4+
1 2 3 4+
1 2 3 4+
1 2 3 4+
Hele
året
Bare vinter-
halvåret
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16. NÅR SPISER DU PÅ HVERDAGER?
17. MENER DU SVARENE I SPØRRESKJEMAET GIR
ET BRUKBART BILDE AV KOSTHOLDET DITT?
18. ER DU FORNØYD MED KROPPSVEKTEN DIN SLIK DEN ER NÅ?
19. KJØNN
Vennligst se etter at du har svart på alle spørsmål.
Takk for innsatsen!
HOVEDMÅLTIDER som frokost, formiddagsmat, middag, kvelds.
MELLOMMÅLTIDER som kaffe, frukt, godteri, snacks m.v.
Er det matvarer/produkter du regelmessig bruker, og som ikke er nevnt i skjemaet?
.................................................................................................................................
.................................................................................................................................
6 8 10 12 14 16 18 20 22 24 2 4
6 8 10 12 14 16 18 20 22 24 2 4
Ja Nei
Ja
Nei, jeg ønsker å slanke meg
Nei, jeg ønsker å legge på meg
Mann Kvinne
Omtrent klokken
Omtrent klokken
12
